肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

晚期卵巢癌：Rubraca的III期ARIEL3研究的全新数据

2019-05-22 不详 网络

rubraca卵巢癌ARIEL3
关注

Clovis近日公布，与接受安慰剂的患者相比，Rubraca的维持治疗能够持续为无进展生存期提供显著益处。在III期ARIEL3研究中接受Rubraca的复发性卵巢癌患者的质量调整时间较长，且没有毒性症状。

Clovis近日公布，与接受安慰剂的患者相比，Rubraca的维持治疗能够持续为无进展生存期提供显著益处。在III期ARIEL3研究中接受Rubraca的复发性卵巢癌患者的质量调整时间较长，且没有毒性症状。

德克萨斯大学安德森癌症中心妇科肿瘤与生殖医学系教授Robert L. Coleman博士说：“复发性卵巢癌维持治疗的目标是在不影响患者生活质量的情况下延缓疾病进展。对QA-PFS和Q-TWiST的数据分析表明，Rubraca作为维持治疗的临床益处在所有试验人群中都得到了保留。这些结果进一步支持了Rubraca在ARIEL3中的正面利益-风险特征”。


原始出处：

http://www.firstwordpharma.com/node/1642173#axzz5oW6BiU1G

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1916107, encodeId=809f191610efc, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Apr 08 07:49:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993300, encodeId=3d9219933004c, content=<a href='/topic/show?id=c1d115e3632' target=_blank style='color:#2F92EE;'>#rubraca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15736, encryptionId=c1d115e3632, topicName=rubraca)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Jul 21 12:49:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651945, encodeId=ec581651945cd, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Tue Sep 24 10:49:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394558, encodeId=83121394558cb, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517117, encodeId=a055151e117b4, content=<a href='/topic/show?id=d87b2e58b8' target=_blank style='color:#2F92EE;'>#ARIEL3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2758, encryptionId=d87b2e58b8, topicName=ARIEL3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44511034184, createdName=12498e8em75暂无昵称, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594596, encodeId=47ce1594596c2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=)]
    2020-04-08 juliusluan78

    #III#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1916107, encodeId=809f191610efc, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Apr 08 07:49:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993300, encodeId=3d9219933004c, content=<a href='/topic/show?id=c1d115e3632' target=_blank style='color:#2F92EE;'>#rubraca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15736, encryptionId=c1d115e3632, topicName=rubraca)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Jul 21 12:49:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651945, encodeId=ec581651945cd, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Tue Sep 24 10:49:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394558, encodeId=83121394558cb, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517117, encodeId=a055151e117b4, content=<a href='/topic/show?id=d87b2e58b8' target=_blank style='color:#2F92EE;'>#ARIEL3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2758, encryptionId=d87b2e58b8, topicName=ARIEL3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44511034184, createdName=12498e8em75暂无昵称, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594596, encodeId=47ce1594596c2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=)]
    2019-07-21 ms1948154235210413

    #rubraca#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1916107, encodeId=809f191610efc, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Apr 08 07:49:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993300, encodeId=3d9219933004c, content=<a href='/topic/show?id=c1d115e3632' target=_blank style='color:#2F92EE;'>#rubraca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15736, encryptionId=c1d115e3632, topicName=rubraca)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Jul 21 12:49:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651945, encodeId=ec581651945cd, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Tue Sep 24 10:49:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394558, encodeId=83121394558cb, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517117, encodeId=a055151e117b4, content=<a href='/topic/show?id=d87b2e58b8' target=_blank style='color:#2F92EE;'>#ARIEL3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2758, encryptionId=d87b2e58b8, topicName=ARIEL3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44511034184, createdName=12498e8em75暂无昵称, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594596, encodeId=47ce1594596c2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=)]
    2019-09-24 lishizhe

    #ACA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1916107, encodeId=809f191610efc, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Apr 08 07:49:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993300, encodeId=3d9219933004c, content=<a href='/topic/show?id=c1d115e3632' target=_blank style='color:#2F92EE;'>#rubraca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15736, encryptionId=c1d115e3632, topicName=rubraca)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Jul 21 12:49:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651945, encodeId=ec581651945cd, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Tue Sep 24 10:49:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394558, encodeId=83121394558cb, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517117, encodeId=a055151e117b4, content=<a href='/topic/show?id=d87b2e58b8' target=_blank style='color:#2F92EE;'>#ARIEL3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2758, encryptionId=d87b2e58b8, topicName=ARIEL3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44511034184, createdName=12498e8em75暂无昵称, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594596, encodeId=47ce1594596c2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=)]
    2019-05-24 siiner

    #晚期卵巢癌#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1916107, encodeId=809f191610efc, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Apr 08 07:49:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993300, encodeId=3d9219933004c, content=<a href='/topic/show?id=c1d115e3632' target=_blank style='color:#2F92EE;'>#rubraca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15736, encryptionId=c1d115e3632, topicName=rubraca)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Jul 21 12:49:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651945, encodeId=ec581651945cd, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Tue Sep 24 10:49:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394558, encodeId=83121394558cb, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517117, encodeId=a055151e117b4, content=<a href='/topic/show?id=d87b2e58b8' target=_blank style='color:#2F92EE;'>#ARIEL3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2758, encryptionId=d87b2e58b8, topicName=ARIEL3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44511034184, createdName=12498e8em75暂无昵称, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594596, encodeId=47ce1594596c2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=)]
    2019-05-24 12498e8em75暂无昵称

    #ARIEL3#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1916107, encodeId=809f191610efc, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Wed Apr 08 07:49:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993300, encodeId=3d9219933004c, content=<a href='/topic/show?id=c1d115e3632' target=_blank style='color:#2F92EE;'>#rubraca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15736, encryptionId=c1d115e3632, topicName=rubraca)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sun Jul 21 12:49:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651945, encodeId=ec581651945cd, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Tue Sep 24 10:49:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394558, encodeId=83121394558cb, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59814, encryptionId=2c9a5981483, topicName=晚期卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517117, encodeId=a055151e117b4, content=<a href='/topic/show?id=d87b2e58b8' target=_blank style='color:#2F92EE;'>#ARIEL3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2758, encryptionId=d87b2e58b8, topicName=ARIEL3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d44511034184, createdName=12498e8em75暂无昵称, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594596, encodeId=47ce1594596c2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri May 24 09:49:00 CST 2019, time=2019-05-24, status=1, ipAttribution=)]
    2019-05-24 智智灵药

    #III期#

    0

相关资讯

Clovis公司的PARP抑制剂美国获批用于复发性卵巢癌的维持治疗

2017年4月6日， Clovis公司宣布获得FDA批准PARP抑制剂Rubraca（rucaparib）片剂， 用于铂类化疗完全或部分缓解的癌症患者的维持治疗，包括复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌。而且Rubraca作为维持治疗药物进行治疗，无须再对患者进行基因突变的检测。